Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.03 AUD | -3.09% | +5.17% | +49.21% |
03:36am | Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50 | MT |
18/04 | Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 114.82 and 54.15 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+49.21% | 3.21B | C+ | ||
+1.77% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+12.24% | 41.34B | B- | ||
-8.83% | 26.59B | C | ||
+7.44% | 25.49B | B- | ||
-23.01% | 18.12B | B | ||
+30.56% | 12.24B | C+ | ||
-1.82% | 11.76B | C+ | ||
+8.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TLX Stock
- Ratings Telix Pharmaceuticals Limited